The state of the enzyme level of antioxidant protection and its nonspecific correction in patients with eczema

Abstract

The variety of developmental mechanisms creates significant difficulties in choosing adequate directions of therapeutic tactics. Priority pathogenetic links, in particular, changes in the state of antioxidant protection, remain insufficiently studied. Objective — determination of the activity of the enzyme level of the antioxidant protection and the development of nonspecific correction of the established violations. Materials and methods. Under observation there were 52 patients with eczema (27 men and 25 women) aged 19 to 57 years. 16 of them were diagnosed with idiopathic, 21 — with infectious (microbial) and 15 — with infectious (mycotic) forms of dermatosis. The control group consisted of 20 healthy persons. The activity of catalase, glutathione peroxidase and superoxide dismutase (SOD) in blood serum was determined. Results and discussion. It has been established that patients with eczema have a labile nature of changes in the enzymatic activity of antioxidant protection, depending on the clinical form of dermatosis. Its total suppression was ascertained only in the presence of mycogenic sensitization. To eliminate the identified violations, PRP therapy and tacrolimus (Protopic) were prescribed, the use of which as part of complex therapy made it possible not only to achieve correction of pathogenetic changes, but also to significantly improve the clinical course of dermatosis. Conclusions. It is advisable to determine the activity of superoxide dismutase, the activity of catalase and glutathione peroxidase to assess the state of the enzyme link of the antioxidant defense in patients with eczema. The inclusion of PRP therapy and tacrolimus (Protopic) in the treatment allows correcting the state of the enzyme link of antioxidant protection and the clinical course of dermatosis. The activity of catalase, glutathione peroxidase and superoxide dismutase can serve as one of the criteria of the effectiveness of treatment prescribed for patients with eczema.